AXA Framlington Health Fund Z Acc
Category Sector Equity Healthcare
This fund can be held in an Investment ISA, SIPP and Investment Account
Last buy/sell price
451.50p
-0.60p (-0.13%)
Fund Code
FMHEA
B6WZJX0
GB00B6WZJX05
Prices updated as at 12 Dec 2025
Prices in GBX
Investment objective
The aim of this Fund is to provide long-term capital growth over a period of 5 years or more. The Fund invests in shares of listed healthcare companies including producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, care providers and managers and other healthcare services companies, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world albeit the Fund tends to be biased towards the US, as this is where the majority of healthcare related companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth.
Important documents: Please ensure that you have read the Key Information Document/Technical Guide
, SDR Consumer facing disclosure, Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.
- Key stats
- Growth
- Performance
- Charges & documents
- Dividends
- Portfolio
- Risk & rating
- Management
Company name
AXA Investment Managers UK Ltd
Fund launch date
24 Apr 1987
Domicile
United Kingdom
UCITS
Yes
Lead manager
Cinney Zhang
Lead manager start date
04 Jul 2023
Lead fund manager biography
Lead manager
Chris Eccles
Lead manager start date
22 Jan 2024
Lead fund manager biography
Chris Eccles is a research analyst who specialises in testing and regulatory affairs. He researches stocks globally and focuses on the Healthcare sector.
Chris joined Impax in March 2019. He started working in the financial industry in 2011 as a research analyst at Morgan Stanley where he focused on European large-cap pharmaceuticals. In 2014, he became a partner at the hedge fund Kola Capital where he worked as a global equities analyst for three years before moving to Stifel in 2017 to work as a Healthcare Specialist.
Chris achieved an MA (Oxon) Physiological Sciences First Class Honours, from the University of Oxford.
Head office
22 Bishopsgate
London
United Kingdom
EC2N 4BQ
Got a question?
Get in touch
we're here to help:
44 20 7003 2345
Mon-Fri 8am to 6pm